Research use only — not for human or veterinary consumptionEvery lot HPLC-assayed before releaseLAL endotoxin report published per lotCold-packed dispatch, next business dayCertificates searchable by lot number21+ · verified laboratory purchasers only Research use only — not for human or veterinary consumptionEvery lot HPLC-assayed before releaseLAL endotoxin report published per lotCold-packed dispatch, next business dayCertificates searchable by lot number21+ · verified laboratory purchasers only
CatalogBundlesLab reports CalculatorGuides AboutContactCompliance
Home / Guides / Cagrilintide, AOD-9604 and MOTS-c Compared
Bench guide

Cagrilintide, AOD-9604 and MOTS-c Compared

Cagrilintide, AOD-9604 and MOTS-c are grouped as metabolic-research peptides but act through three genuinely distinct mechanisms - compared side by side.

On this pageGrouped by interest, not by pathwayCagrilintide: an amylin analogueAOD-9604: a growth-hormone fragmentMOTS-c: a mitochondrial-derived peptideHandling differences across the threeWhy the grouping still makes sense for bench work

Grouped by interest, not by pathway

Cagrilintide, AOD-9604 and MOTS-c are frequently discussed together under a general 'metabolic peptides' heading, and it is worth being precise about what that grouping does and does not mean. They are not three compounds acting on one shared signalling pathway - they are three structurally and mechanistically distinct molecules that happen to be of interest to the same broad area of metabolic research.

Treating them as interchangeable or as variations on one mechanism would be a mistake. Each is worth understanding on its own terms, which is the purpose of comparing them directly here rather than assuming a shared story.

Cagrilintide: an amylin analogue

Cagrilintide is a 32-residue synthetic analogue of amylin, the pancreatic hormone co-secreted with insulin, carrying a C16 fatty diacid side chain for albumin binding that extends its functional half-life. Native human amylin aggregates readily into amyloid fibrils, and the substitutions in this analogue are specifically designed to suppress that aggregation, which is what makes the synthetic version workable at bench concentrations where native amylin is not.

Its lipidation makes it comparatively hydrophobic, and a mildly alkaline buffer dissolves it considerably faster than neutral water - the same handling note covered in the reconstitution guide.

AOD-9604: a growth-hormone fragment

AOD-9604 is a synthetic 16-residue analogue of the C-terminal fragment of human growth hormone, corresponding to residues 177-191 with an added N-terminal tyrosine, and it retains the parent fragment's intramolecular disulfide bridge between cysteine residues at positions 7 and 14.

That disulfide bridge is essential to its conformation and is the reason it belongs in the same handling category as the catalogue's other disulfide-containing sequences: reducing agents such as DTT, TCEP or beta-mercaptoethanol will open the ring and destroy the structure, and should never be present in a buffer used with it.

MOTS-c: a mitochondrial-derived peptide

MOTS-c is a 16-residue peptide encoded within mitochondrial DNA itself - specifically the 12S rRNA region - rather than in the nuclear genome, placing it in the small class of mitochondrial-derived peptides identified since 2015. Its genomic origin, not any amylin- or growth-hormone-related mechanism, is what drives interest in it for mitochondrial and metabolic biology work.

It carries two methionine residues and one tryptophan, making it both oxidation- and light-sensitive - a handling profile shared with several unrelated sequences elsewhere in the catalogue rather than anything specific to metabolic peptides as a class.

Handling differences across the three

Cagrilintide's main handling consideration is dissolution - the alkaline-buffer note above. AOD-9604's is its disulfide bridge and the reducing agents it rules out. MOTS-c's is oxidation and light exposure from its methionine and tryptophan content. None of these three handling profiles resembles either of the other two.

This is a useful illustration of why grouping peptides by research area does not predict their handling requirements - each sequence's chemistry, not its category, determines how it should be stored and reconstituted.

Why the grouping still makes sense for bench work

Even without a shared mechanism, there is a real reason these three appear together in metabolic research: they represent three different experimental angles on energy metabolism and body-composition biology that a lab working in this space may want to compare or use in parallel - an amylin-pathway analogue, a lipolytic growth-hormone fragment, and a mitochondrial signalling peptide.

The value of understanding them side by side is knowing precisely where the comparison stops being valid - at the level of general research interest, not at the level of shared receptor biology or shared handling rules.

Related

This guide is general laboratory reference material relating to the handling of research compounds. It is not medical, veterinary or clinical guidance, and it does not describe or imply any use in humans or animals. All PeptideSeed material is supplied for in-vitro laboratory research only — see the terms of supply.